Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$160.39 USD
+0.34 (0.21%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $160.91 +0.52 (0.32%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
Alnylam Pharmaceuticals, Inc. [ALNY]
Reports for Purchase
Showing records 381 - 400 ( 410 total )
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Oversold in reaction to Roche and Novartis moves; short- and long-term buying
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
With focus now 100% on internal pipeline, Reports 3Q10; expecting liver cancer data next week.
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Life Sciences - R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Novartis passes on option to Alnylam license; days of $100M upfront for platform licenses
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
No major updates on 2Q10 call; Novartis decision on $100M adoption license next major milestone
Provider: RODMAN & RENSHAW, CO.
Analyst: SIMEONIDIS S
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
R&R?s Week in Review: Oncology and Stem Cell Sectors
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Alnylam Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.